Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50p -1.47% 167.50p 165.00p 170.00p 170.00p 167.50p 170.00p 9,333 08:43:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.3 -25.7 -35.0 - 103.73

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp Forums and Chat

Date Time Title Posts
17/11/201719:49Summit - Climbing to new heights23,007
12/11/201702:48Summit Therapeutics' View on Utrophin Modulation-
10/3/201615:43Professor Mark Wilcox Interview on C Diff1
23/5/201409:49Summit Corporation749
22/5/201416:46Summit Corporation plc37

Add a New Thread

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-17 15:04:15165.23250413.07O
2017-11-17 14:49:15165.101,0001,651.00O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 170p.
Summit Corporation has a 4 week average price of 140p and a 12 week average price of 140p.
The 1 year high share price is 265p while the 1 year low share price is currently 140p.
There are currently 61,927,658 shares in issue and the average daily traded volume is 20,385 shares. The market capitalisation of Summit Corporation is £103,728,827.15.
football: The only problem with a "Great RNS" you get the feeling as soon as the share price goes up they will be another RNS stating share options or free shares to the board again dilating the stock.
luminoso: I am not too worried about the Nasdaq losing its love for SUMM in the short term. The perception is that there will be no earth shattering news for some time now, so they are selling off. This can change in a flash with unexpected news as we have seen several times in past year. Apologies if I seem complacent but see nothing to be unduly worried about. Share price is not always a reliable indicator of a company's health, but is a good indicator of the mental health of traders.
chrisatrdg: Per BlackTracker7 from the other board at 19.11 this evening. 'Perspective Not good, not good, not good. SMMT share price on Nasdaq currently just tanked to $10.00. I thought yesterday was bad, but attributed to US Biotech trending down. Now it's gone and done it. Down from $12 earlier this week to now 9.85 on higher than average volume. The recent responses on potential need for new formulations and lack of sufficient evidence to show effectiveness....I will only be holding and selling before DMD Q1 results. Now down to $9.80. Are price targets about to be lowered next? Wind out of the sails and run up it feels like. Finishing off this post before it gets worse.'
football: Got another holding RNS today, they seem to be like buses none for ages then to come along at once
hugus maximus: I know many of us are very optimistic about the value of Summits DMD work but find it difficult to quantify quite what the market cap might one day be. So an interesting post about Sarpeta (see below) that is very encouraging when you refer it's detail to the outlook for Summit. It explains how they are now advancing on further Exon skipping work that may help a further 8% of boys (in addition to their current 13% ... making a maximum of 21% of the DMD population that Sarepta could potentially help ... as opposed to Summit's potential 100%) Then whilst comparing the above, there seems to be much speculation about Sarepta's potential for acquisition: "As time passes and risk is reduced, the price tag for potential acquirers continues to move upward ... I'd say any deal at this point would conservatively start a share price of no less than $80," (EDIT - THAT WOULD MEAN THE SARPETA DMD WORK THEN PRESENTS A COMPANY MARKET CAP OF APPROX $4.5 billion) "... with such a price target still achievable simply by continuing to execute on the commercial side while progressing the DMD pipeline through the clinic. Recent price targets set by Oppenheimer ($76), Credit Suisse ($81), Nomura ($84) and Needham ($75) suggest I'm not too far off." Clearly this writer is a fan of Sarepta, but still an interesting measure of potential for work in the DMD field. I know Glyn acknowledged, whilst chatting at the last AGM, Summit will also be very ripe for the pickings if DMD P2 results start to show something positive. The article in full here:
luminoso: Hmmm. Fair bit of negativity here. These were options deferred from 2016 and they are " subject to achievement of performance conditions pertaining to corporate and programme development milestones." I guess people see things differently when the share price slides a bit. Still plenty to be positive about here IMO. Share price is up 100% from lows last autumn. More cash to come from our friends at Sarepta and something likely for C Diff in summer. Yes, delays to DMD results, but no indication there is anything untoward happening in those trials. There's reasons to be nervous on the macro economic/political front, sure, but SUMM certainly not giving me sleepless nights.
football: Rns Summit Therapeutics plc Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Oppenheimer 27(th) Annual Healthcare Conference, 22 March 2017 at 2:10pm EDT in New York City. A live audio webcast of the presentation will be available through the Investors section on the Company's website, A replay of the webcast will be available soon after the live presentation
hugus maximus: I am no accountant but would expect a more modest $500 million per year C Diff market (that figure clearly dependent on whatever the drug's market price is) ... my stab at expectations over the next few months for C Diff:- As a consequence of a 3rd party major Pharma involvement with C Diff, might Summit realistically be looking for a downpayment of say $75 - 100 million and up to a 30% royalty? Therefore the initial C Diff drug effect on share price stabilising at around £3 ... until further income is eventually generated by sales which would then enhance the share price greatly? (The above having no bearing whatsoever on DMD share price enhancement which is obviously the big prize)
hugus maximus: IMO Sarpeta share interest is a consequence of them finally rolling out eteplirsen after a slow start and the announcement to that effect (a couple of days ago) brings their FDA promise toward some sort of actual fruition. Hence Sarepta's slow drop in share price in the months after the FDA approval date, was due to expectations not being met quickly enough (both in demand and supply). There were many reports of difficulties until this weeks announcement that things had turned around. I wonder if their pipe line Exon 51 is too much a part of the distant future to produce todays share price effect ... although will perhaps have endorsed their position slightly? Maybe Summit are riding on Sarepta's coat tails and the market has turned from hot to cold to warm again about wariness of DMD market in general? Let's hope that the improved eteplirsen pipeline holds for a while, allowing Summit to come in with some serious guns blazing and their shares being bought on their own terms. IMO If Summit can prove with their empirical full comprehensive clinical testing that Ezutromid stands up to the plate (as opposed to the more subjective eteplisen research work which still casts elements of doubt), the DMD market will finally and categorically be banging at their door. EDIT - unless I've missed something majorly significant announced at the San Fran Health Conference which made Summit's shares move up independently last night?
hugus maximus: All IMHO ... Another view about valuations of similar companies and share price can be expressed in the valuation of SAREPTA, a DMD research company that was once in a very similar situation SUMMIT. When it's DMD drug showed promising results during P2 trials it's share price rocketed from under $1 in 2012 to over $50 in 2013 (a drug which only every had a potential cure rate of ~13% of DMD boys) The probable announcement from the FDA next week that Sarepta's failed DMD drug will be stripped of its permission to proceed, will see it's share price fall significantly and find the market looking for the next potential cure. The fact that Summit has so far been seen as a two bit small UK company in a chauvinistic american market place, has been the reason for the share slide. Aside from any value that Summit's C Diff drug has a result of its successful P2 trial results and potential deal with a large pharma, the potential DMD earnings will see the share price reach many multiples of where it is now over the coming months.
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171118 14:21:03